Fluoxetine-induced Raynaud's phenomenon

Biological Psychiatry

Volumn 41, Issue 12, 1997, Pages 1218-1221

  Rudnick, Abraham ^a   Modai, Ilan ^b   Zelikovski, Avigdor ^c  

^a TEL AVIV COMMUNITY MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

Fluoxetine; Myocardial ischemia; Raynaud's phenomenon; Selective serotonin reuptake inhibitors; Serotonin; Vasoconstriction

Indexed keywords

FLUOXETINE;

ADULT; ARTICLE; CASE REPORT; FEMALE; HUMAN; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RAYNAUD PHENOMENON;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIPOLAR DISORDER; FEMALE; FLUOXETINE; HUMANS; MIDDLE AGED; PLETHYSMOGRAPHY; RAYNAUD DISEASE;

EID: 0030975937     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00188-1     Document Type: Article

References (6)

1. Bolte M, Avery D (1993): Case of fluoxetine-induced remission of Raynaud's phenomenon - A case report. Angiology 44:161-163.
2. Fricchione GL, Woznicki RM, Klesmer J, Vlay SC (1993): Vasoconstrictive effects and SSRIs [letter]. J Clin Psychiatry 54:71-72.
3. Gunzberger DW, Martinez D (1992): Adverse vascular effects associated with fluoxetine. Am J Psychiatry 149:1751.
4. Jaffe IA (1995): Serotonin reuptake inhibitors in Raynaud's phenomenon. Lancet 345:1378.
5. Skop BP, Brown TM (1996): Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 37:12-16.
6. Spier SA, Frontera MA (1991): Unexpected deaths in depressed medical inpatients treated with fluoxetine. J Clin Psychiatry 52:377-382.